A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Non-bleeding rate (i.e. women without bleeding from treatment day 9 until the end of treatment)
After three months
No
Bayer Study Director
Study Director
Bayer
Belgium: Federal Agency for Medicinal Products and Health Products
14723
NCT01816815
November 2011
January 2013
Name | Location |
---|